Author Archives: admin


Stem Cell Clinic > Articles by: admin

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

By Global News Feed

NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Read the original here:
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Better Choice Company Chairman Provides Shareholder Update on SRx Health Acquisition and Comments on Recent Debt-to-Equity Transaction

By Global News Feed

TAMPA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, Chairman, Michael Young, today provides shareholders with a update on its SRx Health Solutions, Inc. (“SRx Health”) acquisition and comments on SRx Health’s recent debt-to-equity transaction.

Here is the original post:
Better Choice Company Chairman Provides Shareholder Update on SRx Health Acquisition and Comments on Recent Debt-to-Equity Transaction

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 22,900 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

Read more:
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Edesa Biotech Announces Chief Financial Officer Transition

By Global News Feed

TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities.

Go here to see the original:
Edesa Biotech Announces Chief Financial Officer Transition

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

By Global News Feed

OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the “NYSE American” or the “Exchange”) that it had suspended trading of the Company’s common stock and of its determination to commence delisting proceedings of the Company’s common stock from the Exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company’s common stock. The Company plans to appeal the determination to the Exchange’s Listing Qualifications Panel, although there can be no assurance that any such appeal will be successful.

Read the rest here:
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

Arialief Reviews (SHOCKING REPORT!) Is This Sciatic Nerve Relief Supplement Safe or Overhyped Hoax?

By Global News Feed

HONOLULU, Hawaii, April 05, 2025 (GLOBE NEWSWIRE) -- Arialief is nutritional support specifically designed to offer sciatic nerve relief. It contains selected ingredients that work to alleviate the burning, tingling, and numbness caused by neuropathy. It soothes the inflammation helps calm the overactive nerves and maintains healthy nerve functions. In addition, Arialief also repairs damaged nerves and provides long-term relief.

Original post:
Arialief Reviews (SHOCKING REPORT!) Is This Sciatic Nerve Relief Supplement Safe or Overhyped Hoax?

LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer

By Global News Feed

London, 7 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and world leader in neutrophil immuno-therapies, today announces the appointment of Mark A. Exley, PhD as Chief Scientific Officer (CSO), effective 7 April. The appointment of a CSO with extensive clinical expertise comes at a pivotal time for LIfT, as the Company prepares for clinical trials of its first-in-class immuno-modulator, designed to rejuvenate patient immunity and overcome treatment resistance in solid tumours.

Go here to see the original:
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer

→←